INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Anavex Life Sciences Corp. and Encourages Investors with Losses to Contact the Firm

Los Angeles, California--(Newsfile Corp. - March 14, 2024) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or "the Company") (NASDAQ: AVXL) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Anavex announced the results of its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX®2-73. The study showed a failure to achieve statistically significant achievement of its primary endpoints. Based on this news, shares of Anavex fell by about 35%.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/201733